Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
CTMX CytomX Therapeutics, Inc. daily Stock Chart
CTMX [NASD]
CytomX Therapeutics, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-1.70 Insider Own0.40% Shs Outstand35.36M Perf Week10.10%
Market Cap631.88M Forward P/E- EPS next Y-1.51 Insider Trans-92.69% Shs Float33.96M Perf Month32.08%
Income-62.20M PEG- EPS next Q-0.14 Inst Own76.00% Short Float3.76% Perf Quarter29.68%
Sales30.10M P/S20.99 EPS this Y66.80% Inst Trans2.07% Short Ratio4.45 Perf Half Y-2.08%
Book/sh1.42 P/B12.58 EPS next Y-1.30% ROA-27.00% Target Price28.25 Perf Year10.79%
Cash/sh9.50 P/C1.88 EPS next 5Y5.30% ROE-84.60% 52W Range9.85 - 20.02 Perf YTD62.60%
Dividend- P/FCF4.54 EPS past 5Y- ROI-75.90% 52W High-10.74% Beta-
Dividend %- Quick Ratio5.60 Sales past 5Y- Gross Margin- 52W Low81.42% ATR0.81
Employees78 Current Ratio5.60 Sales Q/Q183.90% Oper. Margin- RSI (14)66.85 Volatility4.38% 4.99%
OptionableYes Debt/Eq0.00 EPS Q/Q-74.60% Profit Margin- Rel Volume1.33 Prev Close17.52
ShortableYes LT Debt/Eq0.00 EarningsAug 07 AMC Payout- Avg Volume286.44K Price17.87
Recom1.70 SMA208.44% SMA5017.72% SMA20026.21% Volume379,788 Change2.00%
Sep-08-17Initiated Wedbush Outperform $26
Mar-27-17Initiated H.C. Wainwright Buy $24
Mar-02-17Initiated Instinet Buy $21
Jan-03-17Downgrade Oppenheimer Outperform → Perform
Nov-02-15Initiated Oppenheimer Outperform $17
Nov-02-15Initiated Jefferies Buy $19
Nov-02-15Initiated BofA/Merrill Buy
Sep-13-17 04:05PM  CytomX to Present at the Cantor Fitzgerald Healthcare Conference GlobeNewswire
Sep-08-17 04:39PM  CytomX Announces Upcoming Trials in Progress Poster Presentations at European Society for Medical Oncology Annual Meeting GlobeNewswire
Aug-23-17 08:52AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CTMX-US : August 23, 2017 Capital Cube
Aug-21-17 06:05PM  CytomX Therapeutics, Inc. Value Analysis (NASDAQ:CTMX) : August 21, 2017 Capital Cube
Aug-13-17 10:25AM  Edited Transcript of CTMX earnings conference call or presentation 7-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-10-17 04:05PM  CytomX to Present at the 2017 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-09-17 08:22AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CTMX-US : August 9, 2017 Capital Cube
Aug-07-17 11:10PM  CytomX Therapeutics reports 2Q loss Associated Press
04:05PM  CytomX Announces Second Quarter 2017 Financial Results and Mid-Year Update Webcast Conference Call GlobeNewswire
12:30PM  Investor Network: CytomX Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-17 04:00PM  Pharma giant Bristol-Myers Squibb just made another big bet on cancer immunotherapy Business Insider
Jul-27-17 08:00AM  CytomX Therapeutics to Announce Second Quarter 2017 Financial Results and Provide Mid-Year Update GlobeNewswire
Jul-19-17 09:07AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CTMX-US : July 19, 2017 Capital Cube -8.85%
Jun-29-17 08:00AM  CytomX Achieves Development Milestone in Strategic Oncology Collaboration with AbbVie for CD71-Targeting Probody Drug Conjugate GlobeNewswire
Jun-28-17 08:00AM  CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-CX-2009 Trial GlobeNewswire +6.64%
Jun-27-17 04:26PM  CytomX Therapeutics, Inc. Value Analysis (NASDAQ:CTMX) : June 27, 2017 Capital Cube
Jun-26-17 08:38AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CTMX-US : June 26, 2017 Capital Cube
Jun-01-17 01:43PM  ETFs with exposure to CytomX Therapeutics, Inc. : June 1, 2017 Capital Cube
May-25-17 08:00AM  CytomX to Present at the Jefferies 2017 Global Healthcare Conference GlobeNewswire
May-22-17 01:31PM  ETFs with exposure to CytomX Therapeutics, Inc. : May 22, 2017 Capital Cube
May-19-17 09:31AM  CytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 Capital Cube
May-17-17 08:00AM  CytomX Announces Upcoming Poster Presentation at American Society for Clinical Oncology Annual Meeting GlobeNewswire
May-16-17 08:43AM  Should CytomX Therapeutics (CTMX) Be On Your Radar Now? Zacks
May-15-17 04:01PM  CytomX Announces Management Team Changes GlobeNewswire
May-05-17 08:14AM  CytomX Therapeutics reports 1Q loss Associated Press
08:00AM  CytomX Announces First Quarter 2017 Financial Results GlobeNewswire
May-04-17 04:41PM  CytomX Therapeutics, Inc. Value Analysis (NASDAQ:CTMX) : May 4, 2017 Capital Cube
May-03-17 08:46AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CTMX-US : May 3, 2017 Capital Cube
Apr-27-17 04:05PM  CytomX Therapeutics to Announce First Quarter 2017 Financial Results GlobeNewswire
Apr-07-17 04:17PM  ETFs with exposure to CytomX Therapeutics, Inc. : April 7, 2017 Capital Cube
Mar-30-17 04:07PM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
08:00AM  CytomX Therapeutics Appoints Marion McCourt to Board of Directors GlobeNewswire
Mar-27-17 07:20AM  Coverage initiated on CytomX Therapeutics by H.C. Wainwright
Mar-24-17 07:47AM  Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved Zacks
Mar-22-17 08:33AM  Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results Zacks
Mar-21-17 11:26AM  Bristol-Myers Squibb and CytomX Therapeutics Extend Deal Zacks
09:30AM  Stocks of Nektar Therapeutics and CytomX Therapeutics Rise on FDA Trial News Accesswire
Mar-20-17 04:10PM  Bristol-Myers Partner Hits 18-Month High On Immuno-Oncology Deal Investor's Business Daily +24.44%
04:10PM  Bristol-Myers Partner Hits 18-Month High On Immuno-Oncology Deal
02:26PM  Heres Why Wells Fargo, eBay, CytomX Therapeutics, Dominion Diamond, and More Are Trending Insider Monkey
02:26PM  Heres Why Wells Fargo, eBay, CytomX Therapeutics, Dominion Diamond, and More Are Trending at Insider Monkey
12:52PM  Bristol-Myers, CytomX Extend Cancer Drug Pact Investopedia
12:52PM  Bristol-Myers, CytomX Extend Cancer Drug Pact at Investopedia
11:56AM  CytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
11:56AM  CytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
11:25AM  Biotechs Remain the Best Place For Stock Picking
11:10AM  A small drug company that's trying to make cancer treatments safer just received a $3.8 billion endorsement
10:55AM  Mondays Top Biopharma Movers
09:38AM  Stocks Edge Lower At The Open; Sprouts Up Again On Merger Talk
09:35AM  Biotech Premarket Movers: CytomX, Aevi, Esperion
09:21AM  CytomX Soars on Bristol-Myers Partnership
07:18AM  CytomX's stock rockets after expanding Bristol-Myers collaboration at MarketWatch
07:02AM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, F
Mar-19-17 07:00PM  CytomX Therapeutics Announces Teleconference and Webcast to Provide Corporate Update GlobeNewswire
Mar-14-17 02:28PM  CytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Mar-08-17 01:04PM  CYTOMX THERAPEUTICS, INC. Financials
Mar-02-17 04:39PM  CytomX Therapeutics reports 4Q loss +9.10%
04:21PM  CYTOMX THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
04:05PM  CytomX Announces Full-Year 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 CytomX Therapeutics Inc Earnings Release - After Market Close
Mar-01-17 08:00AM  CytomX Therapeutics to Announce Full-Year 2016 Financial Results GlobeNewswire +6.32%
Feb-21-17 04:05PM  CytomX Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Feb-14-17 08:29AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CTMX-US : February 14, 2017
Feb-02-17 04:05PM  CytomX to Present at Upcoming Investor Conferences GlobeNewswire
08:00AM  CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-072 Trial GlobeNewswire
Jan-31-17 09:27AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CTMX-US : January 31, 2017
Jan-17-17 11:29AM  ETFs with exposure to CytomX Therapeutics, Inc. : January 17, 2017
Jan-13-17 07:22AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CTMX-US : January 13, 2017
Jan-10-17 04:58PM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure
Jan-09-17 06:55PM  UPDATE: CytomX Announces Time Change for its Presentation at the 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire
08:00AM  CytomX to Present at the 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-03-17 09:25AM  Athene, Barracuda, Energizer, Michael Kors, Tableau Software and Many More in Key Analyst Calls for Tuesday
Dec-27-16 10:32AM  CytomX Therapeutics, Inc. Value Analysis (NASDAQ:CTMX) : December 27, 2016 -8.75%
Dec-26-16 07:29AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CTMX-US : December 26, 2016
Dec-14-16 08:03AM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  CytomX Announces U.S. FDA Clearance of Investigational New Drug Application for Phase 1/2 Clinical Study of Anti-PD-L1 Probody Therapeutic, CX-072 GlobeNewswire
Dec-13-16 02:05PM  Is CytomX Therapeutics Inc (CTMX) A Good Stock To Buy? at Insider Monkey
08:03AM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  CytomX Announces Selection by Bristol-Myers Squibb of First Clinical Candidate Probody From Collaboration GlobeNewswire
07:44AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CTMX-US : December 13, 2016
Dec-12-16 08:52AM  Is Kforce Inc. (KFRC) A Good Stock To Buy? at Insider Monkey
Dec-09-16 01:16PM  ETFs with exposure to CytomX Therapeutics, Inc. : December 9, 2016
Dec-05-16 08:03AM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  CytomX Announces Fourth Target Selection by Bristol-Myers Squibb Under Strategic Oncology Collaboration GlobeNewswire
Nov-22-16 10:50AM  CytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016
Nov-09-16 04:05PM  CytomX to Present at the Jefferies 2016 London Healthcare Conference GlobeNewswire
Nov-03-16 07:36PM  CytomX Therapeutics reports 3Q loss
04:07PM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:05PM  CytomX Therapeutics Announces Third Quarter 2016 Financial Results and Provides Pipeline Update GlobeNewswire
07:07AM  Q3 2016 CytomX Therapeutics Inc Earnings Release - After Market Close
Oct-27-16 08:00AM  CytomX Therapeutics to Announce Third Quarter 2016 Financial Results GlobeNewswire
Oct-21-16 10:26AM  ETFs with exposure to CytomX Therapeutics, Inc. : October 21, 2016
Oct-13-16 08:22AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CTMX-US : October 13, 2016
Sep-23-16 10:07AM  ETFs with exposure to CytomX Therapeutics, Inc. : September 23, 2016 -6.12%
Sep-12-16 10:47AM  ETFs with exposure to CytomX Therapeutics, Inc. : September 12, 2016 +5.93%
Aug-23-16 11:40AM  ETFs with exposure to CytomX Therapeutics, Inc. : August 23, 2016 +6.10%
Aug-10-16 01:30PM  CytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016
Aug-03-16 05:21PM  CytomX Therapeutics reports 2Q loss
04:07PM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:01PM  CytomX Announces Second Quarter 2016 Financial Results GlobeNewswire
Preclinical biotech developing tumor-activated cancer immunotherapies.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McCarthy Sean A.President and CEOSep 01Option Exercise0.959,9309,38414,175Sep 05 06:17 PM
RAY DEBANJANChief Financial OfficerSep 01Sale17.172,50042,92517,126Sep 05 06:18 PM
McCarthy Sean A.President and CEOSep 01Sale17.329,930171,9884,245Sep 05 06:17 PM
McCarthy Sean A.President and CEOAug 31Option Exercise0.9518,75617,72423,001Sep 01 04:28 PM
McCarthy Sean A.President and CEOAug 31Sale17.5018,756328,2604,245Sep 01 04:28 PM
McCarthy Sean A.President and CEOAug 09Option Exercise0.954,7814,5189,026Aug 11 12:50 PM
RAY DEBANJANChief Financial OfficerAug 09Sale15.002,50037,50019,626Aug 11 12:51 PM
McCarthy Sean A.President and CEOAug 09Sale15.004,78171,7154,245Aug 11 12:50 PM
McCarthy Sean A.President and CEOJul 03Option Exercise0.954,7814,5189,026Jul 06 11:20 AM
RAY DEBANJANChief Financial OfficerJul 03Sale15.472,50038,67522,126Jul 06 11:20 AM
McCarthy Sean A.President and CEOJul 03Sale15.524,78174,2014,245Jul 06 11:20 AM
TEPPER ROBERT I10% OwnerJun 29Sale16.0015,000240,00044,777Jun 30 04:00 PM
McCarthy Sean A.President and CEOJun 26Option Exercise0.954,4814,2358,726Jun 27 04:55 PM
GLUCK FREDERICK WDirectorJun 26Sale14.615,00073,050326,643Jun 27 04:57 PM
McCarthy Sean A.President and CEOJun 05Option Exercise0.953002844,545Jun 06 05:57 PM
McCarthy Sean A.President and CEOJun 05Sale15.003004,5004,245Jun 06 05:57 PM
Goeltz II Robert C.Chief Financial OfficerMay 12Option Exercise5.5419,967110,70032,756May 16 04:57 PM
McCarthy Sean A.President and CEOMay 01Option Exercise0.954,7814,5186,760May 02 06:11 PM
McCarthy Sean A.President and CEOMay 01Sale15.704,78175,0621,979May 02 06:11 PM
STARR KEVIN P10% OwnerApr 12Sale16.3628,357463,79331,419Apr 14 04:00 PM
Goeltz II Robert C.Chief Financial OfficerApr 10Option Exercise4.473,00013,41812,789Apr 11 12:51 PM
McCarthy Sean A.President and CEOApr 04Option Exercise0.954,7814,5186,760Apr 05 12:18 PM
McCarthy Sean A.President and CEOApr 04Sale17.504,78183,6681,979Apr 05 12:18 PM
McCarthy Sean A.President and CEOApr 03Option Exercise0.954,7814,5186,760Apr 05 12:18 PM
McCarthy Sean A.President and CEOApr 03Sale16.944,78180,9901,979Apr 05 12:18 PM
THIRD ROCK VENTURES LP10% OwnerMar 27Sale18.00650,00011,700,1955,170,348Mar 27 07:28 PM
THIRD ROCK VENTURES LP10% OwnerMar 23Sale17.001,000,00017,000,2005,820,348Mar 27 07:28 PM
McCarthy Sean A.President and CEOMar 20Option Exercise0.9514,34313,55416,322Mar 21 06:04 PM
Goeltz II Robert C.Chief Financial OfficerMar 20Option Exercise4.4721,51796,24131,306Mar 21 06:05 PM
Goeltz II Robert C.Chief Financial OfficerMar 20Sale19.8121,517426,3409,789Mar 21 06:05 PM
McCarthy Sean A.President and CEOMar 20Sale19.6014,343281,1231,979Mar 21 06:04 PM
Goeltz II Robert C.Chief Financial OfficerMar 09Option Exercise4.472,50011,1829,789Mar 09 07:22 PM
McCarthy Sean A.President and CEOMar 03Option Exercise1.1314,34316,26416,322Mar 03 05:36 PM
McCarthy Sean A.President and CEOMar 03Sale15.0014,343215,1451,979Mar 03 05:36 PM
HUMPHREY RACHELChief Medical OfficerDec 28Option Exercise6.6115,11799,99415,117Dec 29 03:52 PM
SHANNON TIMOTHY MDirectorNov 29Sale11.1822,086247,0083,244,381Dec 01 02:35 PM
Canaan IX L.P.DirectorNov 29Sale11.1822,086247,0083,644,381Dec 01 02:27 PM
Canaan IX L.P.DirectorNov 28Sale11.3320,840236,1423,666,467Nov 28 05:10 PM
SHANNON TIMOTHY MDirectorNov 28Sale11.3320,840236,1423,666,467Nov 28 05:50 PM
SHANNON TIMOTHY MDirectorNov 25Sale11.796,72979,3413,687,307Nov 28 05:50 PM
Canaan IX L.P.DirectorNov 25Sale11.796,72979,3413,687,307Nov 28 05:10 PM
Canaan IX L.P.DirectorNov 23Sale11.8410,890128,9213,694,036Nov 28 05:10 PM
SHANNON TIMOTHY MDirectorNov 23Sale11.8410,890128,9213,694,036Nov 28 05:50 PM
SHANNON TIMOTHY MDirectorNov 22Sale11.7142,550498,0783,704,926Nov 22 07:01 PM
Canaan IX L.P.DirectorNov 22Sale11.7142,550498,0783,704,926Nov 22 06:48 PM
SHANNON TIMOTHY MDirectorNov 21Sale11.7213,548158,7853,747,476Nov 21 06:56 PM
Canaan IX L.P.DirectorNov 21Sale11.7213,548158,7853,747,476Nov 21 06:48 PM
Canaan IX L.P.DirectorNov 18Sale11.6412,805149,0853,761,024Nov 21 06:48 PM
SHANNON TIMOTHY MDirectorNov 18Sale11.6412,805149,0853,761,024Nov 21 06:56 PM
SHANNON TIMOTHY MDirectorNov 17Sale11.5018,971218,2183,773,829Nov 21 06:56 PM
Canaan IX L.P.DirectorNov 17Sale11.5018,971218,2183,773,829Nov 21 06:48 PM
Canaan IX L.P.DirectorNov 16Sale11.5518,517213,9533,792,800Nov 16 07:13 PM
SHANNON TIMOTHY MDirectorNov 16Sale11.5518,517213,9533,792,800Nov 16 07:33 PM
SHANNON TIMOTHY MDirectorNov 15Sale11.4833,064379,4763,811,317Nov 16 07:33 PM
Canaan IX L.P.DirectorNov 15Sale11.4833,064379,4763,811,317Nov 16 07:13 PM
Canaan IX L.P.DirectorNov 14Sale11.2123,744266,0563,844,381Nov 14 04:41 PM
SHANNON TIMOTHY MDirectorNov 14Sale11.2123,744266,0563,844,381Nov 14 05:41 PM
SHANNON TIMOTHY MDirectorNov 11Sale11.2035,391396,4613,868,125Nov 14 05:41 PM
Canaan IX L.P.DirectorNov 11Sale11.2035,391396,4613,868,125Nov 14 04:41 PM
Canaan IX L.P.DirectorNov 10Sale11.0727,135300,3903,903,516Nov 14 04:41 PM
SHANNON TIMOTHY MDirectorNov 10Sale11.0727,135300,3903,903,516Nov 14 05:41 PM
SHANNON TIMOTHY MDirectorNov 09Sale11.0313,730151,4983,930,651Nov 10 04:41 PM
Canaan IX L.P.DirectorNov 09Sale11.0313,730151,4983,930,651Nov 10 04:36 PM
Goeltz II Robert C.Chief Financial OfficerSep 29Option Exercise4.474,00017,8916,000Oct 03 02:32 PM
open in yahoo | open in reuters | open in google